韩国非结核分枝杆菌肺病医疗费用,2015-2019年
该研究从医疗系统长期视角评估了韩国一家三级医院147例非结核分枝杆菌肺病(NTM-PD)患者的医疗费用。中位随访49.7个月期间,中位累积总医疗费用为5044美元(四分位距3586-9680美元),诊断检测和药物是主要费用驱动因素,占总费用的59.6%。
要点
- 中位累积总医疗费用为5044美元,随访中位49.7个月。
- 诊断检测和药物占总费用59.6%,为主要费用驱动因素。
- 脓肿分枝杆菌感染住院和肺部合并症与更高费用相关。
核心结论
- NTM-PD的财务和社会经济负担可能成为韩国主要公共卫生问题,应考虑为NTM-PD患者制定适当策略。
研究设计与样本
- 研究评估了韩国一家三级医院147例NTM-PD患者的长期医疗系统费用。
主要发现
- 中位累积总医疗费用为5044美元(四分位距3586-9680美元),随访中位49.7个月(四分位距33.0-68.2个月)。
- 诊断检测和药物占总费用59.6%。
- 脓肿分枝杆菌感染住院和肺部合并症与更高费用相关。
- 总医疗费用中50.2%为患者自付费用,源于国家医疗保险覆盖有限。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nontuberculous mycobacterial pulmonary disease (NTM-PD) prevalence is a rising public health concern. We assessed the long-term healthcare systems perspective of costs incurred by 147 NTM-PD patients at a tertiary hospital in South Korea. Median cumulative total medical cost in managing NTM-PD patients was US $5,044 (interquartile range US $3,586-$9,680) over 49.7 months (interquartile range 33.0-68.2 months) of follow-up. The major cost drivers were diagnostic testing and medication, accounting for 59.6% of total costs. Higher costs were associated with hospitalization for Mycobacterium abscessus infection and pulmonary comorbidities. Of the total medical care costs, 50.2% were patient co-payments resulting from limited national health insurance coverage. As South Korea faces significant problems of poverty during old age and increasing NTM-PD prevalence, the financial and socio-economic burden of NTM-PD may become a major public health concern that should be considered with regard to adequate strategies for NTM-PD patients.
引用
- Chang S, Kim S, Kang YA, et al. Medical Costs of Nontuberculous Mycobacterial Pulmonary Disease, South Korea, 2015-2019. Emerg Infect Dis. 2024. PMID: 39173659. doi:10.3201/eid3009.231448
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。